1. Methodologic lessons learned from hot flash studies;Sloan;J Clin Oncol,2001
2. US Department of Health and Human Services FDA. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms recommendations for clinical evaluation, 1/2003, www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071643.pdf; 2003 [accessed 01.09.10].
3. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial;Reddy;Obstet Gynecol,2006
4. National Institutes of Health. Assessing and improving measures of hot flashes: summary of an NIH workshop, 1/20/2004, http://nccam.nih.gov/health/hotflashes/ [accessed 01.09.10].
5. European Medicines Agency EMEA. Guidline of clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women, http://www.emea.europa.eu/pdfs/human/ewp/002197en.pdf [accessed 05.10.10].